Immuno-Oncology: Halfway To Adulthood
It Has Been A Tremendous Decade For The Immuno-Oncology Field
Almost a decade on since the first approval for an immuno-oncology therapy, In Vivo analyzes the current landscape, the evolution of combination cancer treatments that use the immune system to target disease and future commercial potential for the market.
You may also be interested in...
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally.